Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Over the last 2 decades, a large number of neurophysiological and neuroimaging studies of
patients with schizophrenia have furnished in vivo evidence for dysconnectivity, ie, abnormal …
patients with schizophrenia have furnished in vivo evidence for dysconnectivity, ie, abnormal …
Glutamate and schizophrenia: phencyclidine, N‐methyl‐d‐aspartate receptors, and dopamine–glutamate interactions
DC Javitt - International review of neurobiology, 2007 - Elsevier
Schizophrenia is a serious mental disorder that affects up to 1% of the population worldwide.
As of yet, neurochemical mechanisms underlying schizophrenia remain unknown. To date …
As of yet, neurochemical mechanisms underlying schizophrenia remain unknown. To date …
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database
NC Allen, S Bagade, MB McQueen, JPA Ioannidis… - Nature …, 2008 - nature.com
In an effort to pinpoint potential genetic risk factors for schizophrenia, research groups
worldwide have published over 1,000 genetic association studies with largely inconsistent …
worldwide have published over 1,000 genetic association studies with largely inconsistent …
MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders
MicroRNAs (miRNAs) are a large family of small non-coding RNAs which negatively control
gene expression at both the mRNA and protein levels. The number of miRNAs identified is …
gene expression at both the mRNA and protein levels. The number of miRNAs identified is …
13 activation mechanisms of the nmda receptor
ML Blanke, AM VanDongen - Biol. NMDA Recept., 2008 - books.google.com
NMDA receptors (NMDARs) are glutamate-gated cation channels with high calcium
permeability that play important roles in many aspects of the biology of higher organisms …
permeability that play important roles in many aspects of the biology of higher organisms …
Presynaptic NMDA receptors: newly appreciated roles in cortical synaptic function and plasticity
R Corlew, DJ Brasier, DE Feldman… - The …, 2008 - journals.sagepub.com
Many aspects of synaptic development, plasticity, and neurotransmission are critically
influenced by NMDAtype glutamate receptors (NMDARs). Moreover, dysfunction of …
influenced by NMDAtype glutamate receptors (NMDARs). Moreover, dysfunction of …
[HTML][HTML] Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease
ME Ehrlich - Neurotherapeutics, 2012 - Elsevier
Huntington's disease is an autosomal dominant disorder caused by a mutation in the gene
encoding the protein huntingtin on chromosome 4. The mutation is an expanded CAG …
encoding the protein huntingtin on chromosome 4. The mutation is an expanded CAG …
Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways
FB Del Guerra, JLI Fonseca, VM Figueiredo… - Journal of …, 2013 - Springer
In the era of greatly improved pharmacological treatment of HIV infection through highly
active antiretroviral therapy (HAART), HIV patients experience reduced viral loads, reduced …
active antiretroviral therapy (HAART), HIV patients experience reduced viral loads, reduced …
Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5
P Paoletti, I Vila, M Rifé, JM Lizcano… - Journal of …, 2008 - Soc Neuroscience
Altered glutamatergic and dopaminergic signaling has been proposed as contributing to the
specific striatal cell death observed in Huntington's disease (HD). However, the precise …
specific striatal cell death observed in Huntington's disease (HD). However, the precise …
Molecular mechanisms underlying levodopa‐induced dyskinesia
P Calabresi, M Di Filippo, V Ghiglieri… - … : official journal of the …, 2008 - Wiley Online Library
Although levodopa remains the most effective drug for the symptomatic treatment of
Parkinson's disease, chronic therapy with this pharmacological compound initiates a …
Parkinson's disease, chronic therapy with this pharmacological compound initiates a …